Physician

Vijaya Korrapati, M.D.

According to 2025 Medicare claims, Vijaya Korrapati, M.D. (NPI: 1033186713) practices hematology/oncology in the Columbia, SC market, with the plurality of this provider's patient population coming from Lexington, SC. This provider's primary affiliated billing organization is LEXINGTON HEALTH INC (NPI: 1932706264; TIN: 85-2276567) and primary practice location at 29169-4848.

Korrapati's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,253 traditional Medicare patients, billed 238,544 HCPCS/CPT codes, and received $3,923,093 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,965 prescription claims across 321 beneficiaries totaling $3,288,950 in drug costs, led by Revlimid (Lenalidomide). DME data shows 26 claims. Open Payments data shows 35 records totaling $771. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,023,370 to $3,923,093. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,326,877 to $3,288,950. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $3,567 and ending at $977.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	604	134,326	$1,023,370
2016	639	146,311	$1,656,812
2017	573	151,921	$1,395,289
2018	700	147,122	$1,575,885
2019	861	193,036	$2,416,024
2020	926	185,403	$2,585,130
2021	1,089	230,192	$3,455,871
2022	1,153	196,065	$3,205,764
2023	1,254	254,223	$4,591,240
2024	1,253	238,544	$3,923,093

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	176	1,399	$1,326,877
2016	204	1,587	$1,278,715
2017	182	1,416	$1,249,823
2018	180	1,354	$1,739,649
2019	198	1,443	$1,836,425
2020	214	1,488	$1,722,714
2021	256	1,650	$2,030,335
2022	311	2,049	$2,499,494
2023	348	2,227	$2,698,393
2024	321	1,965	$3,288,950

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	86	$2,910
2016	N/R	48	$13,361
2017	N/R	132	$6,061
2018	13	172	$11,756
2019	N/R	130	$58,771
2020	N/R	30	$3,586
2021	14	39	$3,558
2022	23	245	$60,406
2023	31	141	$21,857
2024	14	26	$2,641

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	414	762	$59
80053	Blood test, comprehensive group of blood chemicals	314	590	$10
36415	Insertion of needle into vein for collection of blood sample	569	1,294	$8
80048	Blood test, basic group of blood chemicals (calcium, total)	300	679	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	618	1,419	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	34	927	$718,808
Tibsovo	Ivosidenib	12	360	$373,072
Xtandi	Enzalutamide	24	720	$349,362
Vonjo	Pacritinib Citrate	11	330	$164,991
Ninlaro	Ixazomib Citrate	12	336	$151,715

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	14	26	$2,641

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$771	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vijaya Korrapati, M.D.?

Tedicare shows public-source Medicare data for Vijaya Korrapati, M.D. (NPI 1033186713), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vijaya Korrapati, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vijaya Korrapati, M.D.?

Vijaya Korrapati, M.D. is linked to LEXINGTON HEALTH INC (billing NPI 1932706264) in the available physician profile data.

Does Vijaya Korrapati, M.D. have Open Payments data?

Vijaya Korrapati, M.D. has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.